ClinicalTrials.gg

Program

KHN922

A development code. Also written as “KHN922 for injection”.

Its studies are led by Chengdu Kanghong Pharmaceutical Group.

Furthest: phase 2, since Mar 23, 20261 company-led study, 1 open or runningNext primary completion: Apr 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chengdu Kanghong Pharmaceutical Group11 open or runningphase 2since Mar 23, 2026Mar 23, 2026Apr 2028phase 2 · NCT07514975

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 23, 2026First study: phase 2 study in Advanced Solid Tumors CancerFirst studyNCT07514975 · 276 planned · China

Ahead

  1. Apr 2028Primary completion: phase 2 study in Advanced Solid Tumors CancerNCT07514975

TargetBeta

ERBB3 →read by rule
“KHN922 for injection is a dual-payload Antibody Drug Conjugate (ADC) targeting HER3 antigens,intravenous (IV) administration every three weeks (D1) .”study text, by rule · the study

Other programs on ERBB3

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
patritumab deruxtecanMerckphase 317
beruzatatug pelitecanruleMediLink Therapeutics (Suzhou)phase 39
ruzaltatug rezetecanJiangsu HengRui Medicinephase 38
JSKN016ruleAlphamab Oncologyphase 35
SYS6023ruleCSPC Pharmaceutical Groupphase 22
Anti-HER3/Anti-MUC1 Bispecific Antibody-drug Conjugate DM002rulexadcera-biopharmaceutical-suzhou-co-ltdphase 21
Anti-HER3/Exatecan Antibody-drug Conjugate ENV-501rulehummingbird-biosciencephase 21
Anti-EGFR/Anti-HER3 Bispecific Antibody-drug Conjugate AVZO-1418ruleavenzo-therapeutics-incphase 21
CS5007ruleCStone Pharmaceuticalsphase 11
JSKN016HCruleAlphamab Oncologyphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07514975Advanced Solid Tumors Cancer · China2Not yet recruitingApr 2028276

How it is read

Names in the registry

  • “KHN922 for injection”, 1 entry

Codes read as this program: KHN922.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.